Risk management of metabolic disorders in the use of antipsychotics

Cardio-metabolic risk factors and diabetes mellitus type 2 are highly prevalent in patients with schizophrenia. Decrease of metabolic risks associated with use of atypical antipsychotics is connected with the development of specialised programs. They can prevent and treat metabolic disorders. This a...

詳細記述

書誌詳細

出版年:	Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева
主要な著者:	G. E. Mazo, A. O. Kibitov
フォーマット:	論文
言語:	ロシア語
出版事項:	Federal State Budget Scientific Institution National Medical Research Center for Psychiatry and Neurology n.a. V.M. Bekhterev Ministry of Health of the Russian Federation 2018-07-01
主題:	метаболические нарушения антипсихотики индуцируемая антипсихотиками прибавка веса терапевтический менеджмент зипрасидон adverse metabolic effects antipsychotics antipsychotic-inducedweightgain therapeutic management ziprasidone
オンライン･アクセス:	https://www.bekhterevreview.com/jour/article/view/35